Amit Maity

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1029632/publications.pdf

Version: 2024-02-01

53794 32842 10,493 117 45 100 citations h-index g-index papers 117 117 117 17378 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature, 2015, 520, 373-377.	27.8	1,955
2	PI3K/AKT/mTOR Pathway in Angiogenesis. Frontiers in Molecular Neuroscience, 2011, 4, 51.	2.9	1,002
3	Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade. Cell, 2016, 167, 1540-1554.e12.	28.9	830
4	Regulation of glut1 mRNA by Hypoxia-inducible Factor-1. Journal of Biological Chemistry, 2001, 276, 9519-9525.	3.4	633
5	ER stress–mediated autophagy promotes Myc-dependent transformation and tumor growth. Journal of Clinical Investigation, 2012, 122, 4621-4634.	8.2	336
6	The molecular basis for cell cycle delays following ionizing radiation: a review. Radiotherapy and Oncology, 1994, 31, 1-13.	0.6	275
7	Surgery with or without radiation therapy in the management of craniopharyngiomas in children and young adults. International Journal of Radiation Oncology Biology Physics, 2004, 58, 714-720.	0.8	275
8	Design, Implementation, and inÂVivo Validation of a Novel Proton FLASH Radiation Therapy System. International Journal of Radiation Oncology Biology Physics, 2020, 106, 440-448.	0.8	274
9	EGFR Tyrosine Kinase Inhibitors Decrease VEGF Expression by Both Hypoxia-Inducible Factor (HIF)-1–Independent and HIF-1–Dependent Mechanisms. Cancer Research, 2006, 66, 3197-3204.	0.9	256
10	Sp1 Is Involved in Akt-mediated Induction of VEGF Expression through an HIF-1–independent Mechanism. Molecular Biology of the Cell, 2004, 15, 4841-4853.	2.1	206
11	Inhibition of Phosphatidylinositol-3-OH Kinase/Akt Signaling Impairs DNA Repair in Glioblastoma Cells following Ionizing Radiation. Journal of Biological Chemistry, 2007, 282, 21206-21212.	3.4	199
12	Akt1 Activation Can Augment Hypoxia-Inducible Factor-1α Expression by Increasing Protein Translation through a Mammalian Target of Rapamycin–Independent Pathway. Molecular Cancer Research, 2006, 4, 471-479.	3.4	167
13	Nelfinavir Down-regulates Hypoxia-Inducible Factor $1\hat{l}\pm$ and VEGF Expression and Increases Tumor Oxygenation: Implications for Radiotherapy. Cancer Research, 2006, 66, 9252-9259.	0.9	147
14	Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Letters, 2007, 254, 165-177.	7.2	143
15	Effects of ionizing radiation on cell cycle progression. Radiation and Environmental Biophysics, 1995, 34, 79-83.	1.4	133
16	Identification of Putative c-Myc-Responsive Genes: Characterization of <i>rcl</i> , a Novel Growth-Related Geneâ€. Molecular and Cellular Biology, 1997, 17, 4967-4978.	2.3	131
17	PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter. Cancer Research, 2003, 63, 236-41.	0.9	120
18	Phosphatase and Tensin Homologue Deficiency in Glioblastoma Confers Resistance to Radiation and Temozolomide that Is Reversed by the Protease Inhibitor Nelfinavir. Cancer Research, 2007, 67, 4467-4473.	0.9	118

#	Article	IF	CITATIONS
19	Potential molecular targets for manipulating the radiation response. International Journal of Radiation Oncology Biology Physics, 1997, 37, 639-653.	0.8	110
20	The HIV Protease Inhibitor Nelfinavir Downregulates Akt Phosphorylation by Inhibiting Proteasomal Activity and Inducing the Unfolded Protein Response. Neoplasia, 2007, 9, 271-278.	5.3	110
21	Epidermal Growth Factor Receptor Inhibition Modulates the Microenvironment by Vascular Normalization to Improve Chemotherapy and Radiotherapy Efficacy. PLoS ONE, 2009, 4, e6539.	2.5	110
22	Craniospinal radiation in the treatment of biopsy-proven intracranial germinomas: twenty-five years' experience in a single center. International Journal of Radiation Oncology Biology Physics, 2004, 58, 1165-1170.	0.8	108
23	The Tumor Microenvironment in Non–Small-Cell Lung Cancer. Seminars in Radiation Oncology, 2010, 20, 156-163.	2.2	108
24	Cell Cycle-dependent Regulation of the Cyclin B1 Promoter. Journal of Biological Chemistry, 1995, 270, 28419-28424.	3.4	100
25	Radiation Response in Two HPV-Infected Head-and-Neck Cancer Cell Lines in Comparison to a Non–HPV-Infected Cell Line and Relationship to Signaling Through AKT. International Journal of Radiation Oncology Biology Physics, 2009, 74, 928-933.	0.8	93
26	Near complete surgical resection predicts a favorable outcome in pediatric patients with nonbrainstem, malignant gliomas. Cancer, 2004, 101, 817-824.	4.1	91
27	Awakening the immune system with radiation: Optimal dose and fractionation. Cancer Letters, 2015, 368, 185-190.	7.2	91
28	Modulating the tumor microenvironment to increase radiation responsiveness. Cancer Biology and Therapy, 2009, 8, 1994-2001.	3.4	88
29	M-CSF Signals through the MAPK/ERK Pathway via Sp1 to Induce VEGF Production and Induces Angiogenesis In Vivo. PLoS ONE, 2008, 3, e3405.	2.5	87
30	A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours. British Journal of Cancer, 2018, 119, 1200-1207.	6.4	83
31	Association of Antibiotic Exposure With Survival and Toxicity in Patients With Melanoma Receiving Immunotherapy. Journal of the National Cancer Institute, 2021, 113, 162-170.	6.3	81
32	HIV Protease Inhibitors Decrease VEGF/HIF-1α Expression and Angiogenesis in Glioblastoma Cells. Neoplasia, 2006, 8, 889-895.	5.3	78
33	Inhibition of Autophagy as a Strategy to Augment Radiosensitization by the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235. Molecular Pharmacology, 2012, 82, 1230-1240.	2.3	78
34	FLASH Proton Radiotherapy Spares Normal Epithelial and Mesenchymal Tissues While Preserving Sarcoma Response. Cancer Research, 2021, 81, 4808-4821.	0.9	77
35	The Future of Radiobiology. Journal of the National Cancer Institute, 2018, 110, 329-340.	6.3	76
36	Childhood intracranial ependymoma. Cancer, 2007, 110, 432-441.	4.1	71

#	Article	IF	CITATIONS
37	A Phase I Trial of the HIV Protease Inhibitor Nelfinavir with Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer: A Report of Toxicities and Clinical Response. Journal of Thoracic Oncology, 2012, 7, 709-715.	1.1	68
38	Detection of Reactive Oxygen Species via Endogenous Oxidative Pentose Phosphate Cycle Activity in Response to Oxygen Concentration. Journal of Biological Chemistry, 2007, 282, 36790-36796.	3.4	67
39	Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma. International Journal of Radiation Oncology Biology Physics, 2020, 108, 178-188.	0.8	60
40	Increasing Sensitivity to Radiotherapy and Chemotherapy by Using Novel Biological Agents that Alter the Tumor Microenvironment. Current Molecular Medicine, 2009, 9, 1034-1045.	1.3	56
41	Pulmonary function abnormalities in children treated with whole lung irradiation. Pediatric Blood and Cancer, 2006, 46, 222-227.	1.5	54
42	The PI3K/Akt Pathway Regulates Oxygen Metabolism via Pyruvate Dehydrogenase (PDH)-E1α Phosphorylation. Molecular Cancer Therapeutics, 2015, 14, 1928-1938.	4.1	54
43	lonizing radiation inhibits tumor neovascularization by inducing ineffective angiogenesis. Cancer Biology and Therapy, 2005, 4, 1395-1400.	3.4	53
44	Early Changes in Cardiovascular Biomarkers with Contemporary Thoracic Radiation Therapy for Breast Cancer, Lung Cancer, and Lymphoma. International Journal of Radiation Oncology Biology Physics, 2019, 103, 851-860.	0.8	53
45	Hypoxia and VEGF mRNA Expression in Human Tumors. Neoplasia, 2001, 3, 500-508.	5.3	50
46	Comparison of FLASH Proton Entrance and the Spread-Out Bragg Peak Dose Regions in the Sparing of Mouse Intestinal Crypts and in a Pancreatic Tumor Model. Cancers, 2021, 13, 4244.	3.7	48
47	<i>In Vivo</i> Profiling of Hypoxic Gene Expression in Gliomas Using the Hypoxia Marker EF5 and Laser-capture Microdissection. Cancer Research, 2011, 71, 779-789.	0.9	47
48	Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma. Annals of Oncology, 2017, 28, 2179-2184.	1.2	44
49	Treatment of Pediatric Intracranial Arteriovenous Malformations with Linear-Accelerator-Based Stereotactic Radiosurgery: The University of Pennsylvania Experience. Pediatric Neurosurgery, 2004, 40, 207-214.	0.7	43
50	Molecular Pathways: A Novel Approach to Targeting Hypoxia and Improving Radiotherapy Efficacy via Reduction in Oxygen Demand. Clinical Cancer Research, 2015, 21, 1995-2000.	7.0	43
51	Regulation of Histone Deacetylase 4 Expression by the SP Family of Transcription Factors. Molecular Biology of the Cell, 2006, 17, 585-597.	2.1	41
52	Transcriptome analysis of hypoxic cancer cells uncovers intron retention in EIF2B5 as a mechanism to inhibit translation. PLoS Biology, 2017, 15, e2002623.	5.6	41
53	Radiotherapy and the Tumor Microenvironment: Mutual Influence and Clinical Implications. Advances in Experimental Medicine and Biology, 2014, 772, 147-165.	1.6	38
54	A Review of Radiation-Induced Coagulopathy and New Findings to Support Potential Prevention Strategies and Treatments. Radiation Research, 2016, 186, 121-140.	1.5	37

#	Article	IF	Citations
55	Both Increased Stability and Transcription Contribute to the Induction of the Urokinase Plasminogen Activator Receptor (uPAR) Message by Hypoxia. Experimental Cell Research, 2000, 255, 250-257.	2.6	35
56	Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas. Haematologica, 2021, 106, 1705-1713.	3.5	34
57	Dual PI3K/mTOR inhibitor NVP-BEZ235 suppresses hypoxia-inducible factor (HIF)- $1\hat{l}\pm$ expression by blocking protein translation and increases cell death under hypoxia. Cancer Biology and Therapy, 2012, 13, 1102-1111.	3.4	33
58	Increased Expression of Cyclin B1 mRNA Coincides with Diminished G 2 -Phase Arrest in Irradiated HeLa Cells Treated with Staurosporine or Caffeine. Radiation Research, 1994, 140, 393.	1.5	30
59	Modulating Tumor Vasculature through Signaling Inhibition to Improve Cytotoxic Therapy: Figure 1 Cancer Research, 2010, 70, 2141-2145.	0.9	29
60	A phase I study of nelfinavir concurrent with temozolomide and radiotherapy in patients with glioblastoma multiforme. Journal of Neuro-Oncology, 2014, 116, 365-372.	2.9	29
61	Clinical Outcomes of the HIV Protease Inhibitor Nelfinavir With Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non–Small Cell Lung Cancer. JAMA Oncology, 2019, 5, 1464.	7.1	28
62	The effects of radiation on the expression of a newly cloned and characterized rat cyclin B mRNA. International Journal of Radiation Oncology Biology Physics, 1994, 28, 135-144.	0.8	25
63	Low pO2 and \hat{l}^2 -Estradiol Induce VEGF in MCF-7 and MCF-7-5C Cells: Relationship to in vivo Hypoxia. Breast Cancer Research and Treatment, 2001, 67, 51-60.	2.5	23
64	Effects of hyperbaric oxygen exposure on experimental head and neck tumor growth, oxygenation, and vasculature. Head and Neck, 2005, 27, 362-369.	2.0	23
65	Volumetric considerations in radiotherapy for pediatric parameningeal rhabdomyosarcomas. International Journal of Radiation Oncology Biology Physics, 2003, 55, 1294-1299.	0.8	22
66	Onset of mandible and tibia osteoradionecrosis: a comparative pilot study in the rat. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2013, 115, 201-211.	0.4	22
67	Cherenkov imaging for total skin electron therapy (TSET). Medical Physics, 2020, 47, 201-212.	3.0	22
68	Combination of CHEK1/2 inhibition and ionizing radiation results in abscopal tumor response through increased micronuclei formation. Oncogene, 2020, 39, 4344-4357.	5.9	22
69	Sirolimus as a potential radiosensitizer in squamous cell cancer of the head and neck. Head and Neck, 2009, 31, 406-411.	2.0	21
70	Bortezomib sensitizes human head and neck carcinoma cells SQ20B to radiation. Cancer Biology and Therapy, 2007, 6, 156-159.	3.4	18
71	A multiâ€institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation. Cancer, 2017, 123, 1363-1371.	4.1	18
72	HIF and MIFâ€"a nifty way to delay senescence?: Figure 1 Genes and Development, 2006, 20, 3337-3341.	5.9	17

#	Article	IF	Citations
73	New Strategies in Non–Small Cell Lung Cancer: Improving Outcomes in Chemoradiotherapy for Locally Advanced Disease. Clinical Cancer Research, 2011, 17, 4192-4199.	7.0	17
74	A stratified phase I dose escalation trial of hypofractionated radiotherapy followed by ipilimumab in metastatic melanoma: long-term follow-up and final outcomes. Oncolmmunology, 2021, 10, 1863631.	4.6	16
75	Mediastinal masses in children with Hodgkin's disease. An analysis of the Children's hospital of philadelphia and the hospital of the university of pennsylvania experience. Cancer, 1992, 69, 2755-2760.	4.1	15
76	The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma. Clinical Cancer Research, 2021, 27, 6580-6590.	7.0	15
77	Incident Learning in Pursuit of High Reliability: Implementing a Comprehensive, Low-Threshold Reporting Program in a Large, Multisite Radiation Oncology Department. Joint Commission Journal on Quality and Patient Safety, 2015, 41, 160-AP1.	0.7	14
78	Journey Toward High Reliability: A Comprehensive Safety Program to Improve Quality of Care and Safety Culture in a Large, Multisite Radiation Oncology Department. Journal of Oncology Practice, 2016, 12, e603-e612.	2.5	14
79	The implementation and assessment of a quality and safety culture education program in a large radiation oncology department. Practical Radiation Oncology, 2016, 6, e127-e134.	2.1	14
80	A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy. Blood, 2019, 134, 4108-4108.	1.4	14
81	2-deoxy-glucose and radiation: Teaching an old DOG new tricks?. Cancer Biology and Therapy, 2006, 5, 824-826.	3.4	13
82	Acute neurologic toxicity of palliative radiotherapy for brain metastases in patients receiving immune checkpoint blockade. Neuro-Oncology Practice, 2019, 6, 297-304.	1.6	12
83	Testicular Seminoma 16 Years After Treatment for CNS Germinoma. Journal of Neuro-Oncology, 2004, 70, 83-85.	2.9	11
84	Location, Location, Location-Makes All the Difference for Hypoxia in Lung Tumors. Clinical Cancer Research, 2010, 16, 4685-4687.	7.0	11
85	Low-Dose Total Skin Electron Beam Therapy as Part of a Multimodality Regimen for Treatment of Sézary Syndrome. JAMA Dermatology, 2021, 157, 90.	4.1	9
86	Phase 1 trial of nelfinavir added to standard cisplatin chemotherapy with concurrent pelvic radiation for locally advanced cervical cancer. Cancer, 2021, 127, 2279-2293.	4.1	9
87	Galectin-1 and Immune Suppression during Radiotherapy. Clinical Cancer Research, 2014, 20, 6230-6232.	7.0	8
88	Management and outcomes of sinus histiocytosis with massive lymphadenopathy (Rosai Dorfman) Tj ETQq0 0 (O rgBŢ/Ov	erlogk 10 Tf 5
89	Risk of Pneumonitis and Outcomes After Mediastinal Proton Therapy for Relapsed/Refractory Lymphoma: A PTCOG and PCG Collaboration. International Journal of Radiation Oncology Biology Physics, 2021, 109, 220-230.	0.8	7
90	Early Changes in Physical Activity and Quality of Life With Thoracic Radiation Therapy in Breast Cancer, Lung Cancer, and Lymphoma. International Journal of Radiation Oncology Biology Physics, 2021, 109, 946-952.	0.8	7

#	Article	IF	CITATIONS
91	Estrogen Receptor \hat{l}^2 -Mediated Inhibition of Actin-Based Cell Migration Suppresses Metastasis of Inflammatory Breast Cancer. Cancer Research, 2021, 81, 2399-2414.	0.9	7
92	Transient expansion and myofibroblast conversion of adipogenic lineage precursors mediate bone marrow repair after radiation. JCI Insight, 2022, 7, .	5.0	7
93	Alternate Polyadenylation in Rodent Cells Results in Two Differentially Expressed Cyclin B1 mRNAs. Biochemical and Biophysical Research Communications, 1994, 202, 908-914.	2.1	6
94	The chemokine receptor CXCR4: A homing device for hypoxic cancer cells?. Cancer Biology and Therapy, 2006, 5, 1563-1565.	3.4	6
95	An automated electronic system for managing radiation treatment plan peer review reduces missed reviews at a large, high-volume academic center. Practical Radiation Oncology, 2016, 6, e307-e314.	2.1	6
96	Combining Radiation with Immunotherapy: The University of Pennsylvania Experience. Seminars in Radiation Oncology, 2020, 30, 173-180.	2.2	6
97	Palliative Radiotherapy for Diffuse Large B-cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 650-658.	0.4	6
98	Low-Dose Radiotherapy Versus Moderate-Dose Radiotherapy for the Treatment of Indolent Orbital Adnexal Lymphomas. Frontiers in Oncology, 2021, 11, 716002.	2.8	5
99	A Single-Arm PHASE 2A Study of NM-IL-12 (rHu-IL12) in Patients with Mycosis Fungoides-Type CTCL (MF) Undergoing Low-Dose TOTAL Skin Electron BEAM Therapy (LD-TSEBT). Blood, 2016, 128, 4165-4165.	1.4	5
100	Plasma D-Dimer Levels are Elevated in Radiation Oncology Patients. Radiation Research, 2019, 193, 46.	1.5	5
101	Cherenkov imaging for Total Skin Electron Therapy (TSET). , 2018, , .		5
102	Factors associated with event reporting in the pediatric radiation oncology population using an electronic incident reporting system. Practical Radiation Oncology, 2015, 5, e417-e422.	2.1	4
103	Shining a FLASHlight on Ultrahigh Dose-Rate Radiation and Possible Late Toxicity. Clinical Cancer Research, 0, , OF1-OF3.	7.0	4
104	Decreased cyclin B1 expression contributes to G ₂ delay in human brain tumor cells after treatment with camptothecin. Neuro-Oncology, 2001, 3, 11-21.	1.2	3
105	Moderate Colitis Not Requiring Intravenous Steroids Is Associated with Improved Survival in Stage IV Melanoma after Anti-CTLA4 Monotherapy, But Not Combination Therapy. Oncologist, 2022, 27, 799-808.	3.7	3
106	GENERAL PRINCIPLES OF RADIATION AND CHEMORADIATION. Retina, 2009, 29, S30-S31.	1.7	2
107	Tolerability of sequential immune therapy and palliative radiotherapy to the cervical and thoracic spine. Journal of Radiation Oncology, 2018, 7, 233-239.	0.7	2
108	Cherenkov imaging for total skin electron therapy: an evaluation of dose uniformity., 2021, 11628, .		2

AMIT MAITY

#	Article	IF	CITATIONS
109	Consolidative Radiation Therapy Following Autologous Transplantation in Relapsed or Refractory Hodgkin Lymphoma. Blood, 2015, 126, 3195-3195.	1.4	2
110	Concurrent Use of Novel Agents and Radiation Is Tolerated in Lymphoma Patients. Blood, 2019, 134, 2905-2905.	1.4	2
111	Aiding and ABT'ing treatment for glioblastoma. Cancer Biology and Therapy, 2007, 6, 802-804.	3.4	1
112	Impact of Radiotherapy on Hospitalization Burden Surrounding Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2020, 108, E51-E52.	0.8	1
113	Cancer of the Central Nervous System. , 2014, , 938-1001.e16.		1
114	MODULATING THE TUMOR MICROENVIRONMENT TO IMPROVE RADIOTHERAPY. Retina, 2009, 29, S32-S33.	1.7	0
115	Abstract IA-019: Preclinical studies with proton FLASH radiotherapy in mice and canines: Biological effects, biophysical considerations and potential mechanisms. , 2021, , .		0
116	Radiation Therapy for Sarcomas. , 2009, , 277-284.		0
117	Modeling Long-Term Survival in Chemotherapy-Only Versus Combined Modality Therapy in Patients with Early Stage Unfavorable Hodgkin Lymphoma Involving the Mediastinum. Blood, 2016, 128, 2356-2356.	1.4	O